Thus, therapeutic strategies aimed at modulating TGF-β signaling hold promise but require a nuanced understanding of the temporal and phenotypic consequences of TGF-β exposure in tumor-infiltrating NK cells. The gene discussed is TGFB1; the disease is neoplasm.